Amarin (AMRN) To Resume Trading at 7:15AM ET
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Up)
Trade AMRN Now!
Amarin Corporation plc (Nasdaq: AMRN) will resume trading at 7:15AM ET following FDA approval of Vascepa for severe hypertriglyceridemia.
Amarin is awaiting a decision from FDA as to whether Vascepa will be granted five-year new chemical entity (NCE) or three-year new product marketing exclusivity.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Amarin is awaiting a decision from FDA as to whether Vascepa will be granted five-year new chemical entity (NCE) or three-year new product marketing exclusivity.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
- Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
- Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
Create E-mail Alert Related Categories
FDA, Trading Halts
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
